It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
